Merz Therapeutics is a global pharmaceutical organisation with focus on patients with Movement Disorders. XEOMIN® Botulinum Toxin type A is the only treatment licenced for chronic sialorrhea (drooling) in adults due to neurological disorders1† including Parkinson’s disease.  XEOMIN® is recommended by NICE (TA605), within its marketing authorisation, as an option for this indication. It is recommended only if Merz provides it according to the commercial arrangement2.

XEOMIN® is injected into the parotid and submandibular salivary glands providing a reduction in the patient’s salivary flow rate for up to 16 weeks3.

The Merz UK team are offering sialorrhea training and educational meetings both virtually and face to face for healthcare professionals managing sialorrhea in people with Parkinson's. For more information please visit the Merz virtual booth or register your interest at in the contact us section.

Please click here for the XEOMIN® Prescribing Information.

1. XEOMIN® Summary of Product Characteristics (SmPC)

2. NICE Guidance. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea

3. Jost WH. et al. Neurology. 2019 Apr 23;92(17):e1982-e1991. doi: 10.1212/WNL.0000000000007368. Epub 2019 Mar 27

† As of May 2019

Merz Therapeutics video presentation focuses on the treatment of chronic sialorrhea in adults with Parkinson's disease and an integrated patient pathway for chronic sialorrhea in adults – an evidence-based approach, by Dr Javier Carod Artal, Consultant Neurologist Raigmore hospital, NHS Highlands, Scotland.

Downloadable resources